Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
725.72 -31.88 (-4.21%) 01/17/25 [NYSE]
728.05 x 500 728.45 x 100
Realtime by (Cboe BZX)
728.05 x 500 728.45 x 100
Realtime 728.05 +2.33 (+0.32%) 01/17/25
Quote Overview for Fri, Jan 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
725.01
Day High
755.28
Open 747.83
Previous Close 757.60 757.60
Volume 5,560,100 5,560,100
Avg Vol 3,836,050 3,836,050
Stochastic %K 20.53% 20.53%
Weighted Alpha +0.76 +0.76
5-Day Change -74.18 (-9.27%) -74.18 (-9.27%)
52-Week Range 612.70 - 972.53 612.70 - 972.53
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 688,937,600
  • Shares Outstanding, K 949,316
  • Annual Sales, $ 34,124 M
  • Annual Income, $ 5,240 M
  • EBIT $ 13,467 M
  • EBITDA $ 14,994 M
  • 60-Month Beta 0.41
  • Price/Sales 16.06
  • Price/Cash Flow 99.34
  • Price/Book 50.22

Options Overview Details

View History
  • Implied Volatility 35.68% ( +1.70%)
  • Historical Volatility 31.22%
  • IV Percentile 72%
  • IV Rank 40.54%
  • IV High 55.08% on 08/05/24
  • IV Low 22.46% on 06/28/24
  • Put/Call Vol Ratio 0.86
  • Today's Volume 75,795
  • Volume Avg (30-Day) 43,029
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 362,453
  • Open Int (30-Day) 331,403

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 5.22
  • Number of Estimates 8
  • High Estimate 5.56
  • Low Estimate 4.68
  • Prior Year 2.49
  • Growth Rate Est. (year over year) +109.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
725.01 +0.10%
on 01/17/25
Period Open: 778.62
811.35 -10.55%
on 12/20/24
-52.90 (-6.79%)
since 12/17/24
3-Month
711.40 +2.01%
on 11/18/24
Period Open: 917.12
920.92 -21.20%
on 10/18/24
-191.40 (-20.87%)
since 10/17/24
52-Week
612.70 +18.45%
on 01/18/24
Period Open: 628.91
972.53 -25.38%
on 08/22/24
+96.81 (+15.39%)
since 01/17/24

Most Recent Stories

More News
Should You Buy the Dip in Eli Lilly Stock Right Now?

Shares of pharmaceutical stock Eli Lilly are cratering after the company lowered its sales guidance for Q4.

COMP : 6.76 (+0.45%)
LLY : 725.72 (-4.21%)
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when the market...

JPM : 259.16 (+1.92%)
LLY : 725.72 (-4.21%)
3 Unstoppable Stocks to Buy in 2025

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong underlying business prospects that they're practically unstoppable.

CRSP : 40.53 (+0.57%)
VRTX : 422.00 (+1.21%)
LLY : 725.72 (-4.21%)
ISRG : 592.64 (+1.47%)
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk 's Ozempic and Eli Lilly 's (NYSE: LLY) Mounjaro skyrocketing over the past year. However, Eli Lilly recently...

LLY : 725.72 (-4.21%)
Is Novo Nordisk Stock a Buy?

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs. Its shares...

NVO : 78.69 (-5.27%)
LLY : 725.72 (-4.21%)
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales

Key TakeawaysJNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion.Eli Lilly (LLY) announced disappointing preliminary sales numbers, lowering its investor guidance...

AZN : 66.60 (-0.46%)
JNJ : 147.03 (-0.50%)
LLY : 725.72 (-4.21%)
ABBV : 171.56 (-1.23%)
PFE : 26.30 (-0.72%)
Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious

Though negotiated prices won't take effect until 2027, the inclusion of semaglutide has raised concerns about Novo's revenue and potential ripple effects on Eli Lilly's rival drugs.

NVO : 78.69 (-5.27%)
LLY : 725.72 (-4.21%)
Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value

Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025

HBM : 8.59 (-0.58%)
HIMS : 27.85 (-0.32%)
LLY : 725.72 (-4.21%)
TM : 180.78 (-0.39%)
AMZN : 225.94 (+2.39%)
JOBY : 8.17 (-2.39%)
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

These companies lead their respective markets, making them must-haves for buy-and-hold dividend investors.

JNJ : 147.03 (-0.50%)
LLY : 725.72 (-4.21%)
ZTS : 165.89 (-2.05%)
KVUE : 21.10 (-0.42%)
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $860 billion at one point....

NVO : 78.69 (-5.27%)
LLY : 725.72 (-4.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 775.93
2nd Resistance Point 765.61
1st Resistance Point 745.66
Last Price 725.72
1st Support Level 715.39
2nd Support Level 705.07
3rd Support Level 685.12

See More

52-Week High 972.53
Fibonacci 61.8% 835.07
Fibonacci 50% 792.61
Fibonacci 38.2% 750.16
Last Price 725.72
52-Week Low 612.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Master Swing Trading: Strategies for Momentum and Trends